Pacific Biosciences of California Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Thermo Fisher Scientific, as provided by MarketBeat.

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Thermo Fisher Scientific has a consensus target price of $529.6667, suggesting a potential upside of 14.62%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Thermo Fisher Scientific.

Valuation and Earnings

This table compares Pacific Biosciences of California and Thermo Fisher Scientific's gross revenue, earnings per share and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Summary

Thermo Fisher Scientific beats Pacific Biosciences of California on 10 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Illumina, as provided by MarketBeat.

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Illumina has a consensus target price of $365.3158, suggesting a potential downside of 17.16%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Illumina.

Valuation and Earnings

This table compares Pacific Biosciences of California and Illumina's gross revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Illumina's net margins, return on equity and return on assets.

Summary

Illumina beats Pacific Biosciences of California on 9 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Agilent Technologies, as provided by MarketBeat.

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Agilent Technologies has a consensus target price of $100.4619, suggesting a potential downside of 18.75%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Agilent Technologies.

Valuation and Earnings

This table compares Pacific Biosciences of California and Agilent Technologies' gross revenue, earnings per share and valuation.

Agilent Technologies has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Agilent Technologies' net margins, return on equity and return on assets.

Summary

Agilent Technologies beats Pacific Biosciences of California on 8 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Mettler-Toledo International, as provided by MarketBeat.

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Mettler-Toledo International has a consensus target price of $868.0833, suggesting a potential downside of 22.67%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Mettler-Toledo International.

Valuation and Earnings

This table compares Pacific Biosciences of California and Mettler-Toledo International's gross revenue, earnings per share and valuation.

Mettler-Toledo International has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Mettler-Toledo International's net margins, return on equity and return on assets.

Summary

Mettler-Toledo International beats Pacific Biosciences of California on 8 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Bio-Rad Laboratories, as provided by MarketBeat.

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Bio-Rad Laboratories has a consensus target price of $646.00, suggesting a potential upside of 9.27%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Bio-Rad Laboratories.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Pacific Biosciences of California and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Pacific Biosciences of California and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Bio-Rad Laboratories has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Rad Laboratories beats Pacific Biosciences of California on 10 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Pacific Biosciences of California (NASDAQ:PACB) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Waters and Pacific Biosciences of California, as provided by MarketBeat.

Waters presently has a consensus price target of $219.4545, suggesting a potential downside of 19.92%. Pacific Biosciences of California has a consensus price target of $43.50, suggesting a potential upside of 26.67%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Waters.

Volatility & Risk

Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Profitability

This table compares Waters and Pacific Biosciences of California's net margins, return on equity and return on assets.

Insider and Institutional Ownership

91.8% of Waters shares are held by institutional investors. Comparatively, 84.9% of Pacific Biosciences of California shares are held by institutional investors. 1.5% of Waters shares are held by company insiders. Comparatively, 11.6% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Waters and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.

Waters has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.